Mednax, Inc (NYSE:MD) had its price target dropped by Citigroup Inc. from $52.00 to $47.00 in a research note issued to investors on Friday. The firm currently has a “neutral” rating on the stock. Citigroup Inc.’s price objective suggests a potential upside of 8.37% from the stock’s previous close.

Several other equities analysts also recently commented on MD. Robert W. Baird boosted their price target on shares of Mednax from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday. Jefferies Group LLC reiterated a “hold” rating and set a $44.00 target price on shares of Mednax in a research note on Friday. KeyCorp set a $51.00 target price on shares of Mednax and gave the stock a “buy” rating in a research note on Wednesday. Mizuho reiterated a “neutral” rating and set a $48.00 target price (down previously from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Finally, Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the stock. Mednax presently has an average rating of “Hold” and a consensus target price of $54.50.

Mednax (NYSE:MD) traded up $2.02 during trading hours on Friday, hitting $43.37. 2,080,521 shares of the company’s stock traded hands, compared to its average volume of 1,302,315. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.59. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of 12.73, a P/E/G ratio of 1.35 and a beta of 0.32.

Mednax (NYSE:MD) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. The business had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.09 earnings per share. analysts forecast that Mednax will post 3.08 earnings per share for the current year.

WARNING: “Mednax, Inc (MD) Price Target Cut to $47.00” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/03/mednax-inc-md-price-target-cut-to-47-00.html.

In related news, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. QS Investors LLC lifted its position in Mednax by 0.3% in the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after acquiring an additional 12 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Mednax by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock valued at $632,000 after acquiring an additional 47 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its position in Mednax by 1.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 11,300 shares of the company’s stock valued at $784,000 after acquiring an additional 140 shares during the last quarter. Pacer Advisors Inc. lifted its position in Mednax by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after acquiring an additional 145 shares during the last quarter. Finally, State Treasurer State of Michigan lifted its position in Mednax by 0.5% in the second quarter. State Treasurer State of Michigan now owns 38,300 shares of the company’s stock valued at $2,312,000 after acquiring an additional 200 shares during the last quarter. 99.97% of the stock is owned by hedge funds and other institutional investors.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.